Michelle A Rudek

17PUBLICATIONS
108CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 19, 2025
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.

Veronica Rendo, Eudocia Q Lee, Connor Bossi

|Aug 30, 2024
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.

Veronica Rendo, Eudocia Q Lee, Connor Bossi

|Jul 11, 2024
Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer.

Ravi K Anchoori, Ssu-Hsueh Tseng, Hua-Ling Tsai

|Mar 06, 2024
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.

Karisa C Schreck, Roy E Strowd, Louis B Nabors

|Feb 14, 2024
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.

Evanthia T Roussos Torres, Won J Ho, Ludmila Danilova

|Nov 09, 2023
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor.

Michael T Davis, Nicole M Anders, A Dimitrios Colevas

Pageof 3

Frequent Collaborators

3 joint publications

Richard Piekarz

2 joint publications

Eric Laille

2 joint publications

Olatunji B Alese

2 joint publications

R Donald Harvey